An international trial using the Prosigna gene test assessed 50 breast-cancer growth genes to estimate recurrence risk in more than 4,000 newly diagnosed patients over age 40 across the UK, Norway, Sweden, Australia, New Zealand, and Thailand. Patients with low Prosigna scores—over two-thirds—did not receive chemotherapy and instead received hormone therapy alone. Their five-year survival was 93.7%, compared with 94.9% for patients who received chemotherapy. Chemotherapy side effects include fatigue, nausea, hair loss, weakened immunity, and fertility issues. UCL estimated that more than 5,000 NHS patients per year could avoid chemotherapy based on the trial results.
Read at www.bbc.com
Unable to calculate read time
Collection
[
|
...
]